Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Notice of Proposed Sale · 144

Regencell Bioscience Holdings Limited

RGCNASDAQEQUITYCurrent

Notice of Proposed Sale

Filed Nov 17, 2026Accepted Nov 17, 2026, 9:30 AM ESTFiling CIK 1829667Accession 0001213900-26-121152
Share

Structured filing — 144

primary_doc.xml

Open full document ↗

Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.

Proposed-sale notice

Issuer
Regencell Bioscience Holdings Ltd
Issuer CIK
0001829667
SEC file number
001-40617
Phone
852-2155-0823
Person for whose account securities are to be sold
WING YAN WILLIAM LO
Relationships to issuer
Director
Street
9/F Chinachem Leighton Plaza
Street (continued)
29 Leighton Road
City
Causeway Bay
State / country code
K3
Postal code
HK

Securities proposed for sale

Securities proposed for sale · 1 reported row
SecurityProposed unitsAggregate market valueUnits outstandingApproximate sale dateExchangeBroker / market maker
Ordinary shares, par value $0.0000136,001169,924.72495,884,37611/18/2026NasdaqPlatinum Broking Company Limited

Broker / market maker — proposed row 1, entry 1

Name
Platinum Broking Company Limited
Street
21/F LHT Tower
Street (continued)
31 Queen's Road Central
City
Hong Kong
State / country code
K3
Postal code
HK

Acquisition of securities to be sold

Acquisition of securities to be sold · 1 reported row
SecurityAcquiredNature of acquisitionAcquired fromAmount acquiredGift transactionPayment dateNature of payment
Ordinary shares, par value $0.0000111/17/2026Exercise of stock options under the Issuer's share option planThe Issuer36,001N11/17/2026Cash

Prior-sale reporting

Nothing to report for the preceding three months
Y

Remarks

The aggregate market value of the ordinary shares proposed to be sold is based on the closing market price of US$4.72 per ordinary share on November 16, 2026. The number of ordinary shares outstanding reflects the Issuer's number of ordinary shares issued and outstanding as of October 7, 2026, as disclosed in the Issuer's annual report on Form 20-F for the fiscal year ended June 30, 2026 filed with the U.S. Securities and Exchange Commission (the "Commission") on October 7, 2026. In Table I, the acquisition transaction is pursuant to the exercise of stock options granted to the director named in this Form by the Issuer under the Issuer's 2021 share option plan and pursuant to the Issuer's currently effective Form S-8 registration statement (file no. 333-300083) filed with the Commission on November 16, 2026.

Notice signature

Notice date
11/17/2026
Signed
/s/ WING YAN WILLIAM LO

Company context

We are an early-stage bioscience company that focuses on research, development and commercialization of Traditional Chinese Medicine for the treatment of neurocognitive disorders and degeneration, specifically Attention Deficit Hyperactivity Disorder and Autism Spectrum Disorder. Our goal is to save and improve the lives of the patients, their families and caregivers and become a market leader for natural and holistic treatments for neurological disorders globally.

Current securities

Recent company filings

  1. 4 filingNov 17, 2026
  2. S-8 filingNov 16, 2026
  3. 20-F filingOct 7, 2026
  4. 4 filingMay 29, 2026
  5. 6-K filingMay 22, 2026

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.